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the clinic demonstrated that the ab-
solute sizes of their defects had been re-
duced and, of utmost importance to 
these individuals, their visual fields had 
increased. Among the restitution group, 
95 percent of subjects showed an aver-
age increase in their visual field of 4.9· 
(post-chiasmatic injury) or 5.8 0 (optic 
nerve injury). 
In the past, similar improvements in 
vision associated with training have been 
reported. One notable series of studies in-
volving patients with damage to visual 
areas posterior to the thalamus described 
enlargements of the visual field in 40 of 
55 patients following eye-movement 
training2. Another study using similar 
methods concluded that what at first 
seemed to be visual field rehabilitation 
was more likely to be the result of com-
pensatory strategies on the part of sub-
jects, such as biasing their gaze towards 
their blind regiOns. Furthermore, these 
apparent improvements could be elimi-
nated by adopting more rigid experimen-
tal controls such as testing with 
automated perimetry3 (a standard oph-
thalmological technique) suggesting that 
reports of visual restitution should be in-
terpreted with caution. 
This study goes well beyond these ear-
lier reports. Improvement is noted not 
only along the transition zone of the 
blind region but also at islands of phe-
nomenal vision within the blind area. 
Furthermore, improvements were noted 
in patients with optic nerve damage, 
who have not been studied in previous 
clinical protocols. In the Kasten study, 
rigid experimental controls were insti-
gated, such as controlling the direction 
of gaze during training, maintaining a 
stable head pOSition, checking and cali-
brating training profiles during monthly 
cliniC visits, and independently verifying 
all improvements with automated 
perimetry. 
It is unclear why the recovery was so 
marked, although one important aspect 
of the Kasten protocol is that recovery is 
visual field training dependent. Control 
subjects who spent equivalent amounts 
of time using the computer but not per-
forming tasks specific to visual field 
training, did not experience improve-
ments in vision. Based on converging 
evidence from both animal and other 
human studies, the authors propose a 
minimal residual structure hypothesis', 
which postulates that specific visual 
stimulation of as few as 10-15 percent 
surviving neurons is sufficient for recov-
ery of basic visual functions. Of course, 
100 percent survival of neurons of the 
normal vision pathway is the best possi-
ble scenario, but survival of 10-15 per-
cent permits sufficient recovery of 
rudimentary visual function, making a 
remarkable difference in the lives of par-
tially blind individuals. One of the most 
encouraging indications from the 
Kasten study is that computer training 
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may stimulate the few surviving neurons 
in islands of vision with awareness. Use 
of these methods with patients who 
demonstrate islands of vision without 
awarenesss may subsequently result in 
the development of awareness within 
these areas. 
Visual recovery obtained with a com-
puter-based training program, which 
can be used in the comfort and conve-
nience of the home, should provide the 
partially blind with a measure of opti-
mism that some restoration of vision is 
possible. I look forward to these training 
opportunities becoming more widely 
available. 
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In a mouse skin transplant model in which donor and recipient mice differ by only one minor histocompatibility 
antigen, graft tolerance can be induced up to ten days after transplantation, but endures only 
if there is persistence of migratory antigen (pages 1015-1019). 
q~~; =t::;:~;e ~!::¥ei~ ···················i~·~~~~·i·:··~;~·~;~···············KKKK ~~~s:l~~i:~m~h~~m~:f~p l~:h:is~:~~r~~ 
tion"to microorganism*was unmasked in these mice are infused or transplanted 
1973 with the discover by Zinkernagel viral and transplantation immun9logy into unaltered mice of the same strain, 
and Doherty! of the m or histocompati- on common ground~ IUsIng transgenic the gp33 epitope constitutes a single 
bility complex-restrict d host immune techniques, they have produced colonies minor histocompatibility class I-re-
response to the mphocyte chori- of animals that express transgenes en cod- stricted antigen. This results in rejection 
omeningitis virus.(iCMV) and to other ing well characterized viral epitopes. of the transgenic skin by normal mice of 
non-cytopathic/tnicroorganisms. How- With this technology it has been possible the same strain in 70-120 days. In a sub-
ever, the means by which allografts es- to pool the vast reservoir of information group of experiments, the recipient effec-
cape rej.eehon has remained one of the in viral immunology (particularly that ac- tor system was 'pre-armed' by insertion 
/ 
mo~vcontroversial questions in biology quired for LCMV) with the repository of of a T-cell receptor trans gene that in-
ever since the description of neonatal knowledge in transplantation immunol- creases the frequency of naive gp33-spe-
{9lerance in mice, which is strongly asso- ogy, and to address controversial ques- cific precursor cytotoxiC T lymphocytes 
/tiated with donor leukocyte chimerism2• tions about transplantation tolerance3-s. (CTL). The time to rejection of the gp33-
Workers in Zinkernagel's laboratory The transgenic donor mice used in the positive skin grafts was reduced to 15 
have taken a fresh look at this enigma experiments of Ehl et aU, reported on days. These investigators demonstrated 
I I using ~::cKmerimenta!KKKK models that place page 1015 of this issue, ubiquitously ex- that there is an absolutely specific rela-
~=?I 'i S {, ." c' V' cle ')1 W, {1?:; 
'006 NATURE MEDICINE· VOLUME 4 • NUMBER 9 • SEPTEMBER 1998 
... 
....................................................................................................................................................................................... NEWS &: VIEWS 
Q) 
<J) 
c: 
(1) 
............ clonal Maintenance (3) 
-"deletion ~
events, all regulated by 
antigen migration and 
localization, must occur 
in relatively close tempo-
0 
---
c. 
<J) 
.. "" ... ....,.,."...--.... ~ .... ............-....... Q) 
a: 
Q) 
c: 
" E
.§ 
K~ 
.!.I 
c: 
'" 
'" ~
« 
c: 
10 
~ 
0 
.............................................. (2 t) 
Leukocyte Depletion (4) 
Time 
ral proximity for organ 
allografts to be accepted 
by patients and in most 
experimental modelss-B 
(see figure). These are: (1) 
antigen-specific clonal 
exhaustion/deletion of 
the recipient immune re-
action; (2) reciprocal ex-
haustion of the allograft 
The figure depicts the four events that occur in close temporal 
approximation when there is successful organ engraftment: 
double acute clonal exhaustion and subsequent maintenance 
clonal exhaustion (1, 2, and 3 above) plus loss of organ 
immunogenicity due to depletion of the graft's passenger 
leukocytes (4, below). 
immune competent cells 
(passenger leukocytes) 
that migrate to host lym-
phoid organs after trans-
plantation; (3) main-
tenance of the exhaus-
tion of (1) and (2); and 
(4) reduction of the or-
tionship between the gp33 peptide and 
its cognate host CTL clone. 
In their new experiments, the authors 
convincingly show that tolerance to the 
gp33 peptide expressed by the transgenic 
donor skin grafts can be reliably induced 
by conditioning the normal recipients in 
two ways: with three injections of a syn-
thetic gp33 peptide (which is eliminated 
by the unaltered mouse in about 60 days) 
or with a single injection of long-lived 
spleen cells expressing gp33. They assess 
the relative effectiveness of tolerance in-
ducing protocols through their ability to 
prolong survival of the gp33-positive 
skin grafts. Survival results were com-
pared with data on the frequency of 
gp33-specific CTL precursor cells. Both 
the short-lived synthetic gp33 and the 
gp33-expressing spleen cells were tolero-
genic, whether given before or up to ten 
days after skin transplantation. However, 
the full development and perpetuation 
of the tolerogenic effect depended on the 
persistence of gp33 expressed by donor 
spleen cells (that is, it depends on donor 
splenocyte chimerism). Tolerance is not 
sustained by the transgenic skin grafts 
alone in the animals in which original 
non-reactivity was induced with syn-
thetic gp33 peptide. 
The principles defined in this excep-
tionally pure model can be readily iden-
tified in the more complex setting of 
clinical transplantation in which two 
populations of immune competent cells 
confront each other under an umbrella 
of immunosuppression. However, in 
contrast to the simplicity and precision 
of the Ehl model, four interrelated 
gan's antigenicity by progressive deple-
tion of its passenger leukocytes, making 
the allograft an object of increasing im-
mune indifference to the host immune 
system. 
The first three of these events are de-
pendent not only on the persistence of 
antigen, but also on its transport to the 
milieu of organized lymphoid tissue 
where growth factors, different cell 
types, and other factors necessary for ef-
ficient immune activation are locateds. 
The short-lived synthetic gp33 peptide 
administered to recipient mice after 
transplantation in the Ehl experiments 
has been previously shown by the au-
thors to reach these destinations9 . 
However, with bioelimination of the 
synthetic peptide, tolerance cannot be 
maintained by the outlying transgenic 
skin graft, even though the histocompat-
ibility barrier is a weak one (that is, skin 
graft survival for 70-120 days in unma-
nipulated recipients). Similarly, the dis-
appearance of microchimerism in an 
organ recipient presages loss of the outly-
ing allograft due to chronic or acute re-
jectionB.IO• In the Ehl model, skin graft 
rejection was associated with thymus-de-
pendent recovery of precursor CTL. 
The tolerance induced by the gp33 ex-
pressed in the presumably self renewing 
mobile spleen cells is enduring and resis-
tant to tolerance breakdown maneuvers, 
even though the chimeric cells can no 
longer be identified by flow cytometry in 
the blood after 60 days. Terakura et al.l! 
have shown in a rodent allograft model 
that a large proportion of allogeneic 
leukocytes surviving the early post-trans-
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plant period leave the blood and lym-
phoid organs and find niches in non-
lymphoid tissues and organs of the host, 
such as skin and heart. 
Such secondary relocation, a phenom-
enon also seen with widespread non-cy-
topathic pathogens 12, would explain the 
findings of Ehl et al. and also why blood 
samples and lymphoid organ biopsies 
cannot be used to reliably monitor the 
presence or level of chimerism in organ 
allograft recipients. Periodic leakage of 
chimeric cells from the non-lymphOid to 
the lymphoid compartment after trans-
plantation has been suggested as an ex-
planation for the maintenance of clonal 
exhaustions.8 • This is comparable to the 
stable equilibrium between destructive 
and non-destructive immunity described 
in an analogous model of autoimmune 
diabetes mellitus '3• 
Finally, the information provided by 
the Ehl experiments adds to the evi-
dence that giving adjunct donor leuko-
cyte infusions to organ recipients is an 
attempt (that can be safely delayed) to 
augment the normal chain of post-
transplantation tolerogenic events. 
Under the circumstances of conven-
tional organ transplantation, these 
tolerogenic events depend on the mi-
gration of passenger leukocytes from 
the donor allograftsfi-B. Although it is 
disappointing to note that the reported 
tal erogenic protocols used by the au-
thors could not override the degree of 
pre-sensitization induced by pretrans-
plant immunization with LCMV, toler-
ance has been shown by others 14 to be 
produced in presensitized mice by the 
large bolus of hepatic passenger leuko-
cytes released into the recipient circula-
tion after liver transplantation. 
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Watching the pot boil 
Selective antagonists of the two cannabinoid receptors unveil distinct but synergistic peripheral analgesic activities 
for endogenous cannabinoids. 
THE JOURNEY FROM folk medicine, to iden-
tified receptor, to endogenous ligand, 
exemplified so elegantly by the opioids, 
has now been repeated by the cannabi-
noids, a group of compounds whose 
members were first isolated from the mar-
ijuana plant. The recent development of 
selective antagonists of the cannabinoid 
receptors, CBl and CB2, has permitted a 
much greater level of certainty in the in-
terpretation of pharmacological data. It is 
well established that endogenous 
cannabinoids act primarily via the CB 1 
receptor to produce significant analgesia 
in the central nervous system I. However, 
their effects in the periphery were until 
recently unknown. 
Exploiting the newly available 
tive CB 1 and CB2 antagonists, 
and colleagues2 now report in Nature 
two endogenous cannabinoids 
nociception in the peripheral tissues of 
the mouse (in which acute and tonic 
pain is elicited by injection of formalin 
into the hind paw). Fu these 
cannabinoids are synergistic in 
motion of analgesia. 
Since the early sixties, Cannabis 
(marijuana) has been widely used in 
Europe and North America as a recre-
ational drug and has been a cause celebre 
of the counterculture. However, in 
cultural settings and at other 
cannabis has been used as a medicinal 
herb. In fact, it has been known to 
Western medicine as an analgesic for 
over ISO years. Although it was not al-
ways a successful treatment, early inves-
tigators were impressed by its safety, 
appetite-promoting properties and the 
rarity of addiction, particularly when 
compared with that of opiates. 
When the recreational use of cannabis 
became illegal in the United States with 
the passage of the Marijuana Tax Act in 
1937, its medical use in North America 
ground to a halt and, consequently, re~ 
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search on its clinical pharmacology was 
severely curtailed. A few studies showing 
clinically significant analgesic effects of 
smoked cannabis or of one of its major 
purified active ingredients (delta-9-
tetrahydrocannabinol) have been pub-
lished". In contrast to the lack of 
systematic studies, the illicit but wide-
spread availability of cannabis has led in-
dividuals to experiment with the drug 
and to report its 
stimulant and 
cannabinoid receptors, and opioid an-
tagonists do not block its action) it is 
likely that some patients would benefit 
from its use. 
Broad scientific interest in cannabis 
has been rekindled by the cloning of the 
CBl and CB2 receptors (refs. 4,5) and has 
been further spurred by the synthesis of 
the first selective cannabinoid receptor 
antagonists"", which provided direct evi-
dence for the existence of functional en-
dogenous agonists for the two receptors. 
The endogenous cannabinoids anan-
damide, which acts primarily at the CBl 
receptor2, and palmitoylethanolamide 
(PEA), a candidate CB2-like receptor ago-
nist", are synthesized both in the brain 
and in the peripheral tissues. The CBl ag-
onists have analgesic activity in the cen-
tral nervous system 1 and both CBl and 
CB2 agonists have peripheral analgesic 
action2• Cannabinoids may also have 
anti-inflammatory properties. 
In their new study, Calignano and col-
leagues demonstrate that the peripheral 
analgesic effect of anandamide is re-
versed by the CBl antagonist, 
SR141716A, but not by the CB2 antago-
nist, SR144528. The analgeSiC effect of 
PEA is mechanistically distinct from that 
of anandamide, and is blocked by the 
CB2 but not the CBI antagonist. When 
administered together into the hind paw 
(but not into the ventricles of the brain), 
PEA and anandamide act synergistically 
to produce analgeSia, an effect com-
pletely blocked by either the CBl or the 
CB2 antagoniSt. 
ways the most interesting and 
clinically relevant result is 
without administration of an ago-
nist, intravenous injection of either the 
CBI or CB2 antagonist produces hyperal-
gesia. This suggests that, under the con-
ditions of the experiment, there is tonic 
_!~lei:l~e of endogenous CBI and CB2 ago-
nists. Consistent with a tonic endo-
cannabinoid peripheral action, the CBl 
antagonist is much more potent when 
injected directly into the paw than when 
injected intravenously. For technical rea-
sons, the CB2 antagonist could not be 
tested in this paradigm. Additional sup-
port for endogenous cannabinoid release 
comes from the fact that PEA and anan-
damide are found in the rat paw at levels 
sufficient for significant activation of the 
CBl and CB2 receptors. 
There are some loose ends to this story. 
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